Lilly Takes Separate Track On IG; Compliance Guide Is Not A PhRMA Issue
Executive Summary
Lilly plans to comment on the HHS Inspector General's pharmaceutical compliance guidance independent of an industry-wide compliance working group.
You may also be interested in...
Market Share-Based Rebates Are Not Rx Switch Deals, Manufacturers Argue
Drug rebates based on market share and payments to PBMs to disseminate product information are not switching arrangements, a group of 19 manufacturers maintain in comments on the HHS Inspector General's draft compliance guidance
Market Share-Based Rebates Are Not Rx Switch Deals, Manufacturers Argue
Drug rebates based on market share and payments to PBMs to disseminate product information are not switching arrangements, a group of 19 manufacturers maintain in comments on the HHS Inspector General's draft compliance guidance
IG Has Overly “Negative” View Of Sales Incentives, Pfizer Counsel Says
The HHS Inspector General's draft compliance guidance for the pharmaceutical industry takes an overly "negative" stance on compensation for sales representatives, Pfizer Corporate Compliance Counsel Doug Lankler said